As a company that is constantly developing and extending its range of healthcare products, it is important to keep both customers, distributors, medical professionals, patients and shareholders up to date with the latest MDI developments. Along with the latest product and industry news, information for professional healthcare workers such as upcoming conferences and tradeshows where MDI will be represented, will be posted here. As this page will be continually updated, please visit here regularly to see the latest news.
- 15 June 2017 ASX ANNOUNCEMENT Penthrox Regulatory Dossier accepted for review in Canada Medical Developments Internation8 June 2017 ASX ANNOUNCEMENT Presentation at Jefferies 2017 Global Healthcare Conference – June 9, New York Medical Deve5 June 2017 ASX ANNOUNCEMENT MVP signs significant Manufacturing Development Project with CSIRO. Medical Developments In2 June 2017 ASX ANNOUNCEMENT Penthrox replaces Nitrous Oxide in New Zealand Ambulance Medical Developments International27 April 2017 ASX ANNOUNCEMENT MVP Respiratory Devices now available in Costco and circa 10,000 USA pharmacies Medical D12 April 2017 ASX ANNOUNCEMENT Penthrox licensing deal for Russia Medical Developments International Limited (ASX: MVP)10 April 2017 ASX ANNOUNCEMENT MVP’s Respiratory Devices in all Kmart pharmacies in the USA. Medical Developments Intern10 April 2017 ASX ANNOUNCEMENT MVP’s Respiratory Devices in all Walmart stores in the USA. Medical Developments Internat2 March 2017 ASX ANNOUNCEMENT Penthrox: Second order for UK and Ireland Medical Developments International Limited (ASX20th February 2017 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments Internatio8 February 2017 ASX ANNOUNCEMENT Penthrox launched in France and Belgium and first sales. Medical Developments Internati7 February 2017 ASX ANNOUNCEMENT Penthrox: European update Medical Developments International Limited (ASX: MVP) provide23 December 2016 PRESS RELEASE MVP CEO wins Biotech Daily 2016 CEO of the Year8 December 2016 ASX ANNOUNCEMENT Penthrox approved for sale in Taiwan Medical Developments International Limited (ASX: M29 November 2016 ASX ANNOUNCEMENT PENTHROX SUBMITTED FOR REGULATORY APPROVAL IN 22 EUROPEAN COUNTRIES Medical Developmen14 November 2016 POST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order Medical Dev28 October 2016 MVP signs major deal with CSIRO on exclusive rights for some key drugs Medical Developments InternationaPlease refer to the following link for a copy of the MVP FY16 Annual Report Also attached is a link to the MVP AGM NOM
MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox in Canada12 September 2016 MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Ca9 September 2016 ASX ANNOUNCEMENT Penthrox receives regulatory approval in the UAE Medical Developments International Li6 September 2016 ASX ANNOUNCEMENT Licensing deal for Korea Medical Developments International Limited (“MDI”) (ASX: MVP)18 August 2016 ASX ANNOUNCEMENT FY16 Full Year Results For details relating to the full ASX Release, please click on the12 August 2016 ASX ANNOUNCEMENT European Penthrox® Update. Medical Developments International Limited (ASX: MVP) advises9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical D21 June 2016 ASX ANNOUNCEMENT Vive La France: Regulatory Approval Received Medical Developments International Limited (A14 June 2016 ASX ANNOUNCEMENT Licensing deal for Canada Medical Developments International Limited (ASX: MVP) i25 May 2016 ASX ANNOUNCEMENT MVP signs Respiratory deals in the United States and Portugal Medical Developments InternatBell Potter and Patersons has recently initiated coverage on Medical Developments International (ASX:MVP). For a copy o18 February 2016 HALF YEAR REPORT 2015-2016 For a copy of the Half Year Report 2015-16, please click on the following li5 February 2016 ASX ANNOUNCEMENT MVP Completes Acquisition of Breath-A-Tech Medical Developments International Limited (To read our first edition of ASX:MVP Shareholder News, click on the link: Shareholder News January 201627 January 2016 ASX ANNOUNCEMENT Penthrox Launch in the UK and Pricing Approval for Ireland Medical Developments Interna27 January 2016 ASX ANNOUNCEMENT FDA Approves New Range of Respiratory Devices Medical Developments International Limite24 December 2015 ASX ANNOUNCEMENT MVP acquires Avita Medical’s Australian Respiratory Business Medical Developments Inte28 October 2015 ASX ANNOUNCEMENT Green Whistle receives regulatory and marketing approval in the United Kingdom Medical23 September 2015 ASX ANNOUNCEMENT Green Whistle receives regulatory approval in Singapore Medical Developments Interna14 September 2015 ASX ANNOUNCEMENT Mundipharma and Medical Developments International announce a new alliance for the co21 August 2015 ASX ANNOUNCEMENT Preliminary Final Report and Full Year Accounts Medical Developments International Limit29 June 2015 ASX ANNOUNCEMENT Major licensing deal for Europe Medical Developments International Limited (ASX: MV12 May 2015 ASX ANNOUNCEMENT More Penthrox Licensing Agreements Expected To facilitate distributing Penthrox internation8 May 2015 ASX ANNOUNCEMENT Near term planning for the globalisation of Penthrox The approval of Penthrox for use in the6 May 2015 ASX Announcement Penthrox successfully completes its Decentralised Regulatory Approval Procedure in Europe MeTrading Update – 1 May 2015MDI FY15 HY Report (Final)
ASX Announcement – Green Whistle: Positive “Regulatory Approval” feedback from European Regulatory AuthoritiesMedical Developments International Limited (ASX:MVP) is delighted to announce that it has received positive feedback froMedical Developments International (MVP) is delighted to announce it has entered into an exclusive Distribution, LicenseMedical Developments International (MVP) is delighted to advise it has entered into an exclusive agreement with PSUK toSINGAPORE: A year-long trial is being conducted on two medications to ensure patients get a faster and more effective deMedical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in SUpdate on European Marketing Application In November 2013, Medical Developments International (MVP) submitted its regula“THOROUGH QT/QTc” PENTHROX® CLINICAL TRIAL SUCCESSFULLY MEETS ALL PRIMARY AND SECONDARY OBJECTIVES Medical DevelopmentsIn August 2012 MVP announced it had entered into a research and development program with the CSIRO designed to introduceDownload CEO’s & Chairman’s Report as PDF RECORD PROFIT STRONG GROWTH AND 3 CENTS FULLY FRANKED INTERIM20 January 2013 ASX ANOUNCEMENT RESULTS OF PIVOTAL PHASE III CLINICAL TRIAL Methoxyflurane inhalation demonstrated to be27 December 2012 ASX ANNOUNCEMENT Significant Developments and Opportunities in Asthma Devices Consistent with MVP’s str2012 Annual General Meeting Address to Shareholders by Chairman and CEO 24 October, 2012 ADDRESS BY CHAIRMAN – MR. DAVIDCONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (“MDI”) (ASX:MVP) delivered a Record NetMedical Developments International Limited (ASX: MVP) is delighted to confirm the 300th and final patient has been enrolThe Board of Directors of Medical Developments International Ltd. (ASX:MVP) announced a profit guidance upgrade on 22 JuMedical Developments is pleased to announce it has established a UK subsidiary company and appointed a European BusinessFurther Earnings Guidance The Board of Directors of Medical Developments International Ltd. (ASX:MVP) advise the marketMedical Developments is delighted to confirm the following results from its Interim Dividend declared on 23 February, 20